(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Environmental groups urge Germany to cut oil and gas dependence- See the metal guts of a satellite in this wild X-ray view | Space photo of the day for Dec. 4, 2025
- Tesla Stock Hasn’t Looked This Cheap in a While
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Collins Foods to offload 20 Taco Bell outlets in Australia
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Extremely Rare Snub-Nosed Monkey Was Just Born for the First Time Outside of Asia
